ID Administration of fIPV Using Intradermal Adapters vs. BCG Syringe (ID-ADAP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02769923|
Recruitment Status : Completed
First Posted : May 12, 2016
Last Update Posted : September 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|IPV||Device: Westpharma ID adapter Device: Star ID syringe Device: BCG NS||Not Applicable|
The study will be conducted in following two phases.
- Phase I: Ergonometric evaluation and serology: Phase I is based on community based randomized controlled trial with three arms. List of households with child aged 6-12 months will be retrieved from demographic surveillance system. Train CHWs will visit the household and provide relevant information regarding the study to the parents. The children of the parents who provide written informed consent will be screened for eligibility and enrolled into the study. The children accompanied with parents/guardians will be carried to the primary health center of the Dept. of pediatrics and child health, AKU. Baseline 3ml of blood will be collected by trained study phlebotomist in EDT tubes and will be transported to infectious disease research laboratory (IDRL) at AKU. A sample of 450 children will be randomized using sealed envelopes into one of the three study arms. Arm 1, will receive fIPV using WestPharma device, arm 2 will receive fIPV using Star ID syringe and arm 3 will receive fIPV using BCG syringe. The child will be observed for 30 minutes for any adverse event. The research Assistants will interview the parents to fill the socio-demographic questionnaire and vaccinators will fill ergonometric and injection quality questionnaires. The child will be followed after 28 days (4 weeks) of enrollment and another 3ml of blood will be collected by trained phlebotomist. Details of the visit will be recorded in follow-up questionnaire. Both baseline and endline blood samples will be tested for immune response against polio virus 1,2 and 3.
- Phase II: Pilot campaign demonstration: In this phase, investigators will conduct a door to door campaign in the high risk community to provide fIPV using either WestPharma device or Star ID syringe or BCG needle syringe. In this campaign, any child less than 5 years of age, living in the study area and whose parents provide verbal consent will receive intradermal injection of fIPV using any of the three devices by the trained research assistants. This will be a one day campaign in coordination with provincial polio emergency operation center (EOC). About 300 children will receive fIPV using any of the three devices.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||450 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intradermal Administration of Fractional Dose of Inactivated Poliovirus Vaccine Using Intradermal Adapters vs. BCG Syringe: Community Based Randomized Control Trial in Pakistan|
|Study Start Date :||September 2015|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||November 2016|
Active Comparator: Arm A
Westpharma ID Adapter
Device: Westpharma ID adapter
device used for administering intradermal injection
Active Comparator: Arm B
Star ID syringe
Device: Star ID syringe
device used for administering intradermal injection
Active Comparator: Arm C
Device: BCG NS
syringe used for administering intradermal injection
- Difference in immune response against poliovirus type 1, 2 and 3 after 28 days of administration of fractional dose IPV [ Time Frame: up to day 28. ]Seropositivity is defined as reciprocal titers of poliovirus neutralizing antibodies >8; seroconversion is defined as the change from seronegative to seropositive (from reciprocal titer of <8 to >8); and boosting is defined as >4-fold increase in titers. In this study, "immune response" combines both boosting and seroconversion.
- Difference in bleb size after the intradermal injection among three arms [ Time Frame: immediately after injection ]The bleb size will measured immediately after the administration of injection using the millimeter scale.
- Difference in vaccine loss after the intradermal injection among three arms [ Time Frame: immediately after injection ]The measurement is performed by blotting the skin with filter paper to collect liquid that was not delivered into the skin or leaked out after injection. The wet spot on the filter paper will be circled and the diameter of the circle compared to a reference template to quantify the amount of liquid present into the following categories: 0 μl, 0 to 5 μl, 5 to 10 μl, 10 to 20 μl, 20 to 40 μl, more than 40 μl.
- Difference in local adverse events [ Time Frame: within 30 minutes after injection ]local adverse events include redness, itching, etc.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02769923
|Principal Investigator:||Ali F Saleem, FCPS,MSc||The Aga Khan University, Karachi|
|Principal Investigator:||Mohammad T Yousafzai, MPH, MSc||The Aga Khan University, Karachi|